Extensive development program in wide range of tumors

BO-112 is being explored as a monotherapy and in combination as part of an extensive development program, both in-house and led by external investigators in different settings.

A successful Phase 1 clinical trial as monotherapy and a successful phase 1b clinical trial in combination with anti-PD1 have been completed. A Phase 2 combination trial is expected to begin in 2020. Highlight has signed a collaboration with Merck & Co for the Phase 2 evaluation of combination therapies of BO-112 and KEYTRUDA® in patients with select advanced stage solid tumors with liver metastases.

A number of investigator-led trials to explore combinations of BO-112 with checkpoint inhibitors in other indications are planned or underway, with partners including UCLA, California; Manchester University Christie Hospital, UK; and Clinica Universitaria Navarra, Spain. Initial clinical results were presented by Dr. Marquéz-Rodas at the 2018 Congress of the European Society for Medical Oncology.

Highlight Therapeutics is working to understand the key aspects of the mechanism of action of BO-112, particularly in settings where immune checkpoint inhibitors are not effective. Results showing that BO-112 restores sensitivity of JAK1-deficient tumors to adoptive cell transfer were presented by the research group of Dr. Toni Ribas at the 2018 Congress of the Society for Immunotherapy of Cancer.